Summers Value Partners reported a 20.4% net return for their Summers Value Fund LP in Q3 2025, outperforming the Russell 2000 Index ETF (IWM) and the Russell 2000 Value Index ETF (IWN). Year-to-date, the fund is up 4.9% net, with the top 5 holdings showcased for 2025.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was highlighted in Summers Value Partners’ Q3 2025 investor letter. The company, operating as a biopharmaceutical asset, saw a one-month return of 11.58% and a 85.60% increase over the last 52 weeks. On November 18, 2025, LGND closed at $207.05 per share.

Summers Value Partners emphasized Ligand Pharmaceuticals’ unique business model as a royalty aggregator in their Q3 2025 investor letter. The company requires minimal capital for growth, with partners funding development and commercialization. LGND is not among the 30 most popular stocks among hedge funds, with 9 hedge fund portfolios holding the stock at the end of Q2 2025. In Q3 2025, Ligand reported total revenue and other income of $115.5 million on a GAAP basis.

Read more at Yahoo Finance.: What Makes Ligand Pharmaceuticals (LGND) an Investment Choice?